A study of the relationship between the DBH activity in serum and a MspI polymorphic site in intron 9 of the human DBH gene in schizophrenia

Schizophr Res. 1996 Oct 18;22(1):77-80. doi: 10.1016/0920-9964(96)00064-3.

Abstract

Intron 9 of the human dopamine beta-hydroxylase (DBH) gene was amplified using a long PCR procedure in unrelated patients with schizophrenia and unrelated control subjects. MspI digestion of the PCR fragments showed a two allele polymorphism. A1 and A2 Kruskal-Wallis analysis revealed a significant difference in serum DBH activity among the three groups carrying the A1/A2 genotype, the drug-free and drug treated patients, and the control subjects (H = 12.2, df = 2, p < 0.005), and also a significant difference among the three subgroups of drug-treated patients carrying the genotype of A1/A1, A2/A2 or A1/A2 (H = 10.4, df = 2, p < 0.01). The present results suggest that the MspI polymorphic site in intron 9 of the human DBH gene may be associated with alterations of DBH activity in schizophrenia and with the influence of neuroleptic drugs on the DBH activity as well.

MeSH terms

  • Adult
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use
  • Base Sequence
  • Deoxyribonuclease HpaII / genetics*
  • Deoxyribonuclease HpaII / metabolism
  • Dopamine beta-Hydroxylase / blood*
  • Dopamine beta-Hydroxylase / genetics*
  • Dopamine beta-Hydroxylase / metabolism
  • Female
  • Genotype
  • Humans
  • Introns / genetics*
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Schizophrenia / blood*
  • Schizophrenia / drug therapy
  • Schizophrenia / genetics*

Substances

  • Antipsychotic Agents
  • Dopamine beta-Hydroxylase
  • Deoxyribonuclease HpaII